Continuing medical educationAlopecia areata update: Part II. Treatment
Section snippets
Intralesional corticosteroids
Key points Intralesional corticosteroids are the treatment of choice for adults The authors' preference is triamcinolone acetonide 5mg/mL to the scalp and 2.5mg/mL to the face every 4 to 6 weeks Treatment should be stopped if there is no improvement after 6 months
Although intralesional corticosteroids (ILCSs) have been used in the treatment of AA for about 50 years, there are no published randomized controlled trials.1, 3 Hair regrowth has been reported in 71% of patients with subtotal AA treated by
Topical corticosteroids
Key points Topical midpotent corticosteroids are the treatment of choice in children The authors combine topical corticosteroids with minoxidil 5%
Different forms of topical corticosteroids have been used to treat AA, with varying degrees of efficacy. In a randomized, double-blinded, placebo-controlled trial using desoximetasone cream 0.25%, the complete regrowth rates in the active and control groups were 57.6% and 39.2%, respectively.7 These results were not statistically significant when compared with
Topical immunotherapy
Key points Diphenylcyclopropenone (DPCP) is the treatment of choice for adults with more than 50% scalp involvement Sensitization with DPCP 2% is followed by weekly application of the lowest concentration that can cause mild irritation Squaric acid dibutylester is an alternative in patients who do not develop allergic reaction to DPCP Treatment should be stopped if there is no improvement after 6 months The success rate is 50% to 60%, with a relapse rate up to 62% at a median period of 2 and a half years
Systemic corticosteroids
Key points Daily, weekly, and monthly pulse corticosteroids have been used with varying success The use of systemic corticosteroids is limited by their side effect profile and a higher rate of relapse
Several forms of systemic corticosteroids have been described in the literature with better success rates in multifocal AA and less favorable results with ophiasis and universalis AA.61 In a placebo-controlled trial of oral prednisolone 200 mg once weekly for 3 months, it was shown that a moderate regrowth of
Cyclosporine
Key points Cyclosporine has been used alone or in conjunction with corticosteroids with a success rate up to 76.6% Cyclosporine use is limited by its side effects and high relapse rate
Cyclosporine is an immunosuppressant agent that inhibits helper T-cell activation and suppresses interferon gamma (IFN-γ) production. Success rates with oral cyclosporine range from 25% in some trials81 to 76.7% in others if combined with methylprednisolone.82 Notably, however, AA has been reported in several organ transplant
Management plan
At the patient's first visit, a careful medical history and a good physical examination should be carried out, including an examination of all hair-bearing areas and nails. Full information about his or her disease, including the relapsing nature of AA, prognosis, and risk/benefit ratio of treatment options, should be provided. It is important that the physician spends enough time with the patient to answer his or her questions and to address the psychosocial effects of AA, because this affects
Vitamin D
1, 25-dihydroxycholecalciferol [1, 25(OH)2D3] is the biologic active form of the vitamin D3.125 Vitamin D has a multitude of biologic effects interacting with the innate and adaptive immune system, mainly leading to its downregulation.126 It regulates the differentiation of B cells, T cells, dendritic cells, and the expression of Toll-like receptors.126 There is growing evidence that vitamin D may help in several autoimmune diseases like multiple sclerosis and type I diabetes mellitus,127 lupus,
Summary
There has been little progress in the treatment of AA in the past decade, and ILCSs are still the preferred method of treatment for most patients. Newer topical and systemic agents (eg, biologics) have been tried, but the outcomes have been unattractive. We are still in need of developing treatment options for refractory cases and for specific hair-bearing sites (ie, eyelashes) where treatment choices are almost nonexistent. Because of higher psychiatric morbidity in patients with AA,
References (131)
- et al.
Alopecia areata investigational assessment guidelines—part II. National Alopecia Areata Foundation
J Am Acad Dermatol
(2004) - et al.
Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells
Biochem Biophys Res Commun
(2007) - et al.
Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis
J Am Acad Dermatol
(2003) - et al.
Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography
J Invest Dermatol
(1984) - et al.
Action of topical minoxidil in the bald stump-tailed macaque
J Am Acad Dermatol
(1987) - et al.
Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo
J Invest Dermatol
(1992) Potential mechanisms of minoxidil-induced hair growth in alopecia areata
J Am Acad Dermatol
(1987)Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata
J Am Acad Dermatol
(1987)Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata
J Am Acad Dermatol
(1987)Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy
J Am Acad Dermatol
(1987)
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
J Am Acad Dermatol
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
J Am Acad Dermatol
A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
J Am Acad Dermatol
1-chloro-2,4-dinitrobenzene depletes glutathione in rat skin and is mutagenic in Salmonella typhimurium
Mutat Res
Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability
J Am Acad Dermatol
Squaric acid and esters: analysis for contaminants and stability in solvents
J Am Acad Dermatol
Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone
J Am Acad Dermatol
Alopecia areata: a long term follow-up study of 191 patients
J Am Acad Dermatol
Severe urticarial reaction to diphenylcyclopropenone therapy for alopecia areata
J Am Acad Dermatol
Efficacy of topical sensitizers in the treatment of alopecia areata
J Am Acad Dermatol
Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone
J Invest Dermatol
Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients
J Am Acad Dermatol
Placebo-controlled oral pulse prednisolone therapy in alopecia areata
J Am Acad Dermatol
The risks of systemic corticosteroid use
Dermatol Clin
308-nm excimer laser therapy in alopecia areata
J Am Acad Dermatol
Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation
J Am Acad Dermatol
Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine
J Am Acad Dermatol
The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis
J Am Acad Dermatol
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study
J Am Acad Dermatol
Subcutaneous efalizumab is not effective in the treatment of alopecia areata
J Am Acad Dermatol
Interventions for alopecia areata
Cochrane Database Syst Rev
Alopecia areata: evidence-based treatments
Semin Cutan Med Surg
Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector
Br J Dermatol
A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata
Br J Dermatol
Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream
Arch Dermatol
Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial
Int J Dermatol
Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial
J Eur Acad Dermatol Venereol
Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response
Dermatologica
Alterations in scalp blood flow after the epicutaneous application of 3% minoxidil and 0.1% hexyl nicotinate in alopecia
Br J Dermatol
Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells
Br J Dermatol
The effect of topical minoxidil on hair follicular cycles of rats
J Dermatol
Minoxidil: mechanisms of action on hair growth
Br J Dermatol
In vitro suppression of human lymphocyte activity by minoxidil
Int J Dermatol
Treatment of alopecia areata by anthralin-induced dermatitis
Arch Dermatol
Evaluation of anthralin in the treatment of alopecia areata
Arch Dermatol
Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin
Exp Dermatol
Guidelines for the management of alopecia areata
Br J Dermatol
Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin
Arch Dermatol
Comparison of azelaic acid and anthralin for the therapy of patchy alopecia areata: a pilot study
Am J Clin Dermatol
Mutagenic and cell transforming activities of 1-chlor-2,4-dinitrobenzene (DNCB) and squaric-acid-dibutylester (SADBE)
Arch Toxicol
Cited by (249)
The extracellular matrix of the skin: systemic diseases with local manifestations
2023, Biochemistry of Collagens, Laminins and Elastin: Structure, Function and Biomarkers, Third EditionAlopecia Areata: Current Treatments and New Directions
2023, American Journal of Clinical DermatologyDiagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
2023, Dermatology and TherapyBeard Alopecia: An Updated and Comprehensive Review of Etiologies, Presentation and Treatment
2023, Journal of Clinical MedicineAllergen desensitization reduces the severity of relapsed alopecia areata in dust-mite allergic patients
2023, Experimental Dermatology
Funding sources: None.
Conflicts of interest: Dr Shapiro is a consultant for Johnson and Johnson Inc. Drs Shapiro and McElwee are cofounders of TrichoScience Innovations Inc. The other authors, editors, and peer reviewers have no relevant financial relationships.